Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,214 across all filing types
Latest filing 2025-06-18 Foreign Filer Report
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 1 TO FORM 6-K
Foreign Filer Report
2025-06-18 English
Immediate Report of Meeting to be held on July 21, 2025
Director's Dealing Classification · 1% confidence The document text consists of multiple formal declarations titled "Declaration of Director's Qualification" under Section 224(b) of the Israeli Companies' Law - 1999. These declarations are made by individuals (Alexander Rabinovich, Shlomo Shalev, Doron Turgeman) confirming their qualifications, experience, and lack of disqualifying convictions to serve as directors for XTL BIOPHARMACEUTICALS Ltd. This type of filing relates directly to the composition and suitability of the company's governing body (Board of Directors). Among the provided codes, 'Board/Management Information' (MANG) is the most appropriate fit, as it covers announcements of changes or qualifications related to the board of directors or senior management. It is not a general regulatory filing (RNS), an earnings release (ER), or a proxy statement (PSI).
2025-06-15 English
Immediate Report of Meeting to be held on July 21, 2025
Proxy Solicitation & Information Statement Classification · 1% confidence The document is explicitly titled 'FORM 6-K' and is filed 'For the Month of June 2025'. The content details the announcement of an 'Annual and Extraordinary General Meeting of Shareholders' (the Meeting) scheduled for July 21, 2025. It includes the Notice, Proxy Statement (Exhibit 99.1), Proxy Card (Exhibit 99.2), and Voting Instruction Card (Exhibit 99.3). The core purpose of this filing is to provide the necessary materials and notice for shareholders to vote on matters at the upcoming general meeting, which strongly aligns with the definition of Proxy Solicitation & Information Statement (PSI). Although it relates to an AGM, the document itself is the regulatory filing (Form 6-K) containing the proxy materials, making PSI the most specific fit among the provided options, as AGM-R is reserved for presentations/materials *shared during* the meeting, not the pre-meeting solicitation documents.
2025-06-15 English
Immediate Report of Meeting to be held on July 21, 2025
AGM Information Classification · 1% confidence The document explicitly states it is a 'Immediate Report of Meeting' concerning the 'convening of meeting' for an 'extraordinary meeting' scheduled for 21/07/2025. The agenda items include discussing the auditor's report, appointing auditors, and re-electing directors, which are typical items for a General Meeting. The structure and content strongly indicate a formal notice related to a shareholder meeting, which aligns best with the 'AGM Information' category (AGM-R), even though it is an extraordinary meeting, as it deals with the mechanics and agenda of a shareholder assembly. It is not a proxy statement (PSI) itself, but a notice of the meeting being convened.
2025-06-15 English
REPORT OF FOREIGN PRIVATE ISSUER
Foreign Filer Report
2025-06-13 English
FORM 20-F For the fiscal year ended December 31, 2024
Annual Report Classification · 1% confidence The document is an official 'Form 20-F' filed with the U.S. Securities and Exchange Commission (SEC). Form 20-F is the mandatory annual report for foreign private issuers. The text explicitly identifies itself as an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the fiscal year ended December 31, 2024. It includes a table of contents covering financial information, management discussion, and risk factors, which is characteristic of a comprehensive annual report. FY 2024
2025-05-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.